

RECEIVED 012/042
CENTRAL FAX CENTER

JUL 19 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

12

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Ballard, K. A.

Attorney Docket Number 15270J-004743US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.K./	855	7,195,761	03-27-2007	Holtzman et al.	
	878	7,189,819	03-13-2007	Basi et al.	
	879	7,179,892	02-20-2007	Basi et al.	
	880	7,014,855	03-21-2006	Schenk	
	881	6,982,084	01-03-2006	Schenk	
	686	6,972,127	12-06-2005	Schenk	
	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	866	6,962,984	11-08-2005	Ishiwata et al.	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	685	2005/0163788 A1	07-28-2005	Schenk	
	884	2005/0152878 A1	07-14-2005	Solomon et al.	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	784	2005/0118651 A1	06-02-2005	Basi et al.	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	882	6,787,139	09-07-2004	Schenk	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082762 A1	04-29-2004	Basi et al.	
	849	6,727,349	04-27-2004	LaRosa et al.	
	870	2003/0207828 A1	11-06-2003	Ishiwata et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	804	2003/0202972 A1	10-30-2003	James et al.	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	748	6,610,493	08-26-2003	Citron et al.	

Examiner
Signature

/Daniel Kolker/

Date
Considered

01/03/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61102386

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	12	Attorney Docket Number
/D.K./	730	2003/0166557 A1	09-04-2003	Minna et al.

869	2003/0135035 A1	07-17-2003	Shannon
883	6,582,945	06-24-2003	Raso
871	2003/0092145 A1	05-15-2003	Jira et al.
702	6,548,640	04-15-2003	Winter
725	6,538,124	03-25-2003	Idusogie et al.
726	6,528,624	03-04-2003	Idusogie et al.
710	6,407,213	06-18-2002	Carter et al.
776	6,372,716	04-16-2002	Bush et al.
720	6,277,375	08-21-2001	Ward
777	6,270,757	08-07-2001	Warne
778	6,267,958	07-31-2001	Andya et al.
795	6,210,671	04-03-2001	Co
724	6,194,551	02-27-2001	Idusogie et al.
704	6,180,370	01-30-2001	Queen et al.
747	6,175,057	01-16-2001	Mucke et al.
719	6,165,745	12-26-2000	Ward et al.
723	6,121,022	09-19-2000	Presta et al.
711	6,054,297	04-25-2000	Carter et al.
722	5,869,048	02-09-1999	Presta et al.
867	5,866,129	02-02-1999	Chang et al.
707	5,859,205	01-12-1999	Adair et al.
860	5,858,981	01-12-1999	Schreiber et al.
771	5,837,268	11-17-1998	Potter et al.
885	5,798,102	08-25-1998	McMichael et al.
779	5,770,700	06-23-1998	Webb et al.
780	5,744,132	04-28-1998	Warne et al.
770	5,733,548	03-31-1998	Restifo et al.
705	5,693,761	12-02-1997	Queen et al.
721	5,677,425	10-14-1997	Bodmer et al.
717	5,648,260	07-15-1997	Winter et al.
718	5,624,821	04-29-1997	Winter et al.
764	5,601,827	02-11-1997	Collier et al.

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61102386

RECEIVED
CENTRALFAXCENTER

JUL 19 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	12	Attorney Docket Number	15270J-004743US
/D.K.	708	5,585,089	12-17-1996	Queen et al.	
	781	5,385,887	01-31-1995	Yim et al.	
	868	5,245,015	09-14-1993	Fung et al.	
	819	5,227,159	07-13-1993	Miller	
	703	5,225,539	07-06-1993	Winter	
	740	4,883,666	11-28-1989	Sabel et al.	
	691	11/245,524	filed 10-07-2005	Schenk	
	692	11/245,916	filed 10-07-2005	Schenk	
	763	60/067,740	filed 12-02-1997	Schenk	
	760	60/067,219	filed 12-03-1997	Weiner et al.	
	761	60/079,697	filed 03-27-1998	Weiner et al.	
▼	762	60/080,970	filed 01-11-1999	Schenk	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
/D.K.	853	EP	921 189	B1	01-12-2005			
	842	EP	1 481 992	A2, A3	12-01-2004			
	786	EP	758 901	B1	02-26-1997			
	787	EP	758 248	B1	02-19-1997			
	738	EP	626 390	A1	11-30-1994			
	802	EP	597 101	A1	05-18-1994			
	820	EP	285 159	A1	10-05-1988			
	848	WO	05/026211	A2, A3	03-24-2005			
	701	WO	05/014041	A2	02-17-2005			
	757	WO	04/108895	A2, A3	12-16-2004			
	847	WO	04/071408	A2	08-26-2004			
	797	WO	04/055164	A2	07-01-2004			
	846	WO	04/044204	A2, A3	05-27-2004			
▼	786	WO	03/105894	A1	12-24-2003			
	845	WO	03/072036	A2, A3	09-04-2003			

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61102386

RECEIVED
CENTRAL FAX CENTER

JUL 19 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	12	Complete If Known		
/D.K./	799	WO	03/39485	A2	05-15-2003	
	756	WO	03/16467	A2, A3	02-27-2003	
	803	WO	03/16466	A2	02-27-2003	
	788	WO	03/15691	A2	02-27-2003	
	798	WO	03/09817	A2	02-06-2003	
	827	WO	02/96937	A2	12-05-2002	
	789	WO	01/05355	A2	01-25-2001	
	772	WO	99/10008	A1	03-04-1999	
	813	WO	97/03192	A3	01-30-1997	
	854	WO	95/07301	A1	03-16-1995	
	698	WO	95/06407	A1	03-09-1995	
	736	WO	94/10569	A1	05-11-1994	
	814	WO	94/00153	A1	01-06-1994	
	821	WO	91/16928	A1	11-14-1991	



Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

12

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Ballard

Attorney Docket Number 15270J-004743US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.K./	773	ALBERTS ET AL., <i>Molecular Biology of the Cell</i> , 2nd Edition, pages 266-267, Garland Publishing Inc., New York (1989).	
/D.K./	875	ARD et al., "Scavenging of Alzheimer's Amyloid β -Protein by Microglia in Culture," <i>J. Neuroscience Research</i> , 43:190-202 (1996).	
/D.K./	881	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	790	BALES et al., "Administration of an Anti- β Fab Fragment to APP ^{V717F} Transgenic Mice Reduces Neuritic Plaque," <i>Abstract P4-398</i> , Page S587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based	
/D.K./	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti- β antibody," <i>J. Clin. Invest.</i> , 116(3):825-832 (2006).	
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against BA4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).	
	754	BLASBERG et al., "Regional Localization of Glioma-assoiated Antigen Defined by Monoclonal Antibody 81C6 <i>In Vivo</i> : Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987).	
	840	BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <i>Free Press</i> , 7/23/01.	
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <i>J. Biol. Chem.</i> , 275(22):16941-16947 (2000).	
	832	BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <i>Exp. Neurol.</i> , 120(2):245-263 (1993).	
▼	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <i>Am. J. Public Health</i> , 88:1337-1342 (1998).	

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

RECEIVED
CENTRAL FAX CENTER

4017/042

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<i>Complete If Known</i>			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	6			of	12
					Attorney Docket Number
					15270J-004743US

/D.K./	791	BUSSIÈRE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A β Immunotherapy on Their Clearance," <i>Am. J. Pathology</i> , 165(3):987-995 (2004).	
	823	CASSELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <i>Functional Neurobiology of Aging</i> , Hof et al., eds., Academic Press (2001).	
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <i>J. Neurosci. Res.</i> , 58:120-129 (1999).	
	766	COICO et al., <i>Immunology A Short Course, Fifth Edition</i> , pages 18-24 (2003).	
	859	COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <i>Society for Neuroscience</i> , abstract, Washington DC, 11/12-16/05. 2005	
	687	COX et al., "Adjuvants—a classification and review of their modes of action," <i>Vaccine</i> , 15(3):248-256 (1997).	
	836	DAS et al., "Reduced effectiveness of A β -42 immunization in APP transgenic mice with significant amyloid deposition," <i>Neurobiology of Aging</i> , 22:721-727 (2001).	
	769	DAVIS, S. S., "Nasal Vaccines," <i>Advanced Drug Delivery Reviews</i> , 51:21-42 (2001).	
	861	DE FELICE et al., " β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <i>Cell Mol. Neurobiol.</i> , 22(5/6):545-563 (2002).	
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <i>Rev. In Neurosciences</i> , 5:213-225 (1994).	
	745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <i>Experimental Neurology</i> , 149:329-340 (1998).	
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <i>J. Molecular Recognition</i> , 4(2-3):85-91 (1991).	
▼	862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <i>Blood</i> , 88(1):202-210 (1996).	

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

RECEIVED
CENTRAL FAX CENTER

018/042

JUL 19 2007

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1440B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

12

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Ballard

Attorney Docket Number 15270J-004743US

/D.K./	817	DU et al., "α ₂ -Macroglobulin as a β-Amyloid Peptide-Binding Plasma Protein," <u>J. Neurochemistry</u> , 69(1):299-305 (1997).
	811	European Search Report of 5/22/06 for European Application 06075704.4-2107.
	812	European Search Report of 5/22/06 for European Application 06075479.3-2107.
	852	European Search Report of 1/16/07 for European Application 04776252.1-2405.
	873	GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD): From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <u>Autoimmunity Rev.</u> , 5:33-39 (2000).
	694	GUPTA et al., "Adjuvants for human vaccines—current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).
	807	HARA et al., "Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <u>J. Alzheimer's Disease</u> , 6:483-488 (2004).
	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <u>Int. J. Biochem. & Cell Biol.</u> , 35:1608-1613 (2003).
	887	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164:4178-4184 (2000).
	792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <u>J. Biol. Chem.</u> , 276(22):18748-18756 (2001).
	834	KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <u>Biochemistry</u> , 41:922-928 (2002).
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987).
	863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <u>J. Neuropath Exp. Neurol.</u> , 60(3):274-279 (2001).
↓	843	KLYUBIN et al., "Anti-Aβ Antibodies Prevent Block of Long-Term Potentiation In the CA1 Area of Rat Hippocampus InVivo by naturally Produced Aβ Oligomers," <u>Neurobiology of Aging</u> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

RECEIVED
CENTRAL FAX CENTER

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk, D. B.		
		Art Unit	1649		
		Examiner Name	Ballard		
Sheet	8	of	12	Attorney Docket Number	15270J-004743US

/D.K./	794	KOFLER et al., "Immunoglobulin Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <i>J. Clin. Invest.</i> , 82:852-860 (1988).	
	826	KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	
	888	KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	
	695	KUO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <i>J. Biol. Chem.</i> , 271(8):4077-4081 (1996).	
	833	KUO et al., "Comparative Analysis of Amyloid- β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains," <i>J. Biol. Chem.</i> , 276(16):12991-12998 (2001).	
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <i>Appl. Pathol.</i> , 3(1-2):39-54 (1985).	
	816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β -Amyloid," <i>J. Biol. Chem.</i> , 269(38):23403-23406 (1994).	
	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <i>J. Molecular Neuroscience</i> , 24:105-113 (2004).	
	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <i>Immunity & Aging</i> , 1:1-2 (2004).	
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <i>J. Histochemistry and Cytochemistry</i> , 32(3):322-328 (1982).	
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <i>Critical Rev. Clin. Lab. Sci.</i> , 41(1):1-39 (2004).	
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <i>Clin. Exp. Immunol.</i> , 50(2):390-396 (1982).	
↓	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <i>PNAS</i> , 86:337-341 (1989).	

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

RECEIVED 020/042
CENTRAL FAX CENTER

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/724,319
(use as many sheets as necessary)		Filing Date	November 27, 2000
Sheet	9	of	12
		First Named Inventor	Schenk, D. B.
		Art Unit	1649
		Examiner Name	Ballard
		Attorney Docket Number	15270J-004743US

/D.K./	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).	
	822	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.	
	886	MORGAN et al., "The N-terminal end of the C _H 2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc _Y RII and Fc _Y RII binding," <u>Immunology</u> , 86:319-324 (1995).	
	841	OKIE, S., "Promising Vaccine Targets Ravager of Minds," <u>Washington Post</u> , page A01, 5/8/01.	
	808	OKURA et al., "Nonviral A _B DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <u>PNAS</u> , 103(25):9619-9624 (2006).	
	829	PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development," <u>J. Am. Soc. Exp. Neurotherapeutics</u> , 2:3-14 (2005).	
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997).	
	806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.	
	850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.	
	872	PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093.	
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>Immunological Methods</u> , 120:133-143 (1989).	
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).	
	864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <u>Int. J. Cancer</u> , 55(1):148-152 (1993).	
▼	837	Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," American Academy of Neurology, 5/7/01.	

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

RECEIVED
CENTRAL FAX CENTER

021/042

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/724,319
(use as many sheets as necessary)		Filing Date	November 27, 2000
Sheet	10	First Named Inventor	Schenk, D. B.
	of	Art Unit	1649
	12	Examiner Name	Ballard
		Attorney Docket Number	15270J-004743US

/D.K./	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α ," <u>PNAS</u> , 92:11294-11298 (1995).
/D.K./	809	QU et al., " $\text{A}\beta_{42}$ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <u>J. Neurological Sciences</u> , 244:151-158 (2006).
	838	ROSENBERG, R. N., "The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders," pages 1-5.
/D.K./	865	ROSES, A.D., "Apolipoprotein E alleles as risk factors in Alzheimer's disease," <u>Annu. Rev. Med.</u> , 47:387-400 (1996).
	851	SALDANHA et al., "A single backmutation in the human k1V framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <u>Molecular Immunology</u> , 36:709-719 (1999).
	759	SCHENK et al., "Current progress in beta-amyloid immunotherapy," <u>Curr. Opin. Immunology</u> , 16(5):599-606 (2004).
	768	SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997).
	856	SEUBERT et al., "Antibody Capture of Soluble $\text{A}\beta$ does not Reduce Cortical $\text{A}\beta$ Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , (2007).
	818	SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995).
	828	Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05.
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).
	874	SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <u>Biochem. J.</u> , 314:701-707 (1996).
	839	TRAVIS, J., "A Vaccine for Alzheimer's Disease?®," <u>Science News Online</u> , 156(2) pages 1-3 downloaded from internet (1999).
▼	857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <u>Science</u> , 309:731-734 (2005).

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<i>Complete If Known</i>			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	11			of	12
				Attorney Docket Number	15270J-004743US

/D.K./	767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996).	
	844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/1/90).	
	815	URMONEIT et al., "Cerebrovascular Smooth Muscle CElls Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997).	
	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W84R in a French family," <u>Kidney International</u> , 61:907-912 (2002).	
	775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).	
	835	VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <u>Progress in Neurobiology</u> , 61:305-312 (2000).	
	690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002).	
	800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003).	
	801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).	
	688	Webster's New World Dictionary of American English, Third College Edition, page 1078 (1988).	
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.	
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.	
▼	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.	

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	12			of	12
					Attorney Docket Number
					15270J-004743US

/D.K./	728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <i>Scand. J. Immunol.</i> , 46(2):175-179 (1997).	
		ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- β : Potential Therapeutic for Alzheimer's Disease," <i>Abstract P4-420, Page 5593, presented at 793 Poster Session P4: Therapeutics and Therapeutic Strategies: Therapeutic Strategies</i>	
		Amyloid-Based	
/D.K./	825	ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <i>Current Protocols in Mol. Biol.</i> , Supp 41, pages 10.15.1 through 10.15.9 (1998).	
/D.K./	810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <i>Neurobiology of Disease</i> , 14:365-379 (2003).	

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	1	of	2	Attorney Docket Number	15270J-004743US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (<i>if known</i>)			
/D.K./	892	6,923,964	08-02-2005	Schenk	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)				
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	09/724,319
				<i>Filing Date</i>	November 27, 2000
				<i>First Named Inventor</i>	Schenk, Dale B.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Ballard, Kimberly
Sheet	2	of	2	<i>Attorney Docket Number</i>	15270J-004743US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/D.K./	898	ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of <i>Bordetella pertussis</i> toxin subunit S1," <u>PNAS</u> , 87:1347-1351 (1990).		<input type="checkbox"/>
	891	CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," <u>Drugs R D</u> , 7(3):187-193 (2006).		<input type="checkbox"/>
	893	DE LA CRUZ et al, "Immumogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <u>J Biol Chem</u> , 263(9):4318-4322 (1988).		<input type="checkbox"/>
	896	GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Integr Comp Physiol</u> , 259:R1131-R1138 (1990).		<input type="checkbox"/>
	895	KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <u>FEBS Letters</u> , 351:80-84 (1994).		<input type="checkbox"/>
	889	LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <u>Proc. Natl. Acad. Sci.</u> , 95:13266-13271 (1998).		<input type="checkbox"/>
	890	PEREZ et al., "The β -Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <u>J. Neurosci</u> , 17(24):9407-9414 (1997).		<input type="checkbox"/>
	897	WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," <u>Am J Physiol Gastrointest Liver Physiol</u> , 259:G687-G691 (1990).		<input type="checkbox"/>
▼	894	WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of <i>Salmonella</i> ," <u>PNAS</u> , 86:4726-4730 (1989).		<input type="checkbox"/>

Examiner Signature	/Daniel Kolker/	Date Considered	01/03/2008
--------------------	-----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.